Conduit Pharmaceuticals (CDT) Institutional Ownership $2.86 +0.07 (+2.32%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$2.92 +0.05 (+1.75%) As of 07/3/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Conduit Pharmaceuticals (NASDAQ:CDT)CurrentInstitutional OwnershipPercentage3.29%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$160.19MNumber ofInstitutional Sellers(last 12 months)0 Get CDT Insider Trade Alerts Want to know when executives and insiders are buying or selling Conduit Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Conduit Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025Citadel Advisors LLC526,268$36K0.0%+177.0%51.094% 2/13/2025Barclays PLC892,350$61K0.0%+6.5%86.636% 2/12/2025Geode Capital Management LLC584,984$40K0.0%+36.8%56.795% 1/30/2025Rhumbline Advisers1,028,702$71K0.0%+5,034.0%1.000% (Data available from 1/1/2016 forward) CDT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CDT shares? During the previous two years, the following institutional investors and hedge funds held shares of Conduit Pharmaceuticals shares: Rhumbline Advisers ($71K), Barclays PLC ($61K), and Geode Capital Management LLC ($40K), Citadel Advisors LLC ($36K).Learn more on Conduit Pharmaceuticals' institutional investors. What percentage of Conduit Pharmaceuticals' stock is owned by institutional investors? 3.29% of Conduit Pharmaceuticals' stock is owned by institutional investors. Learn more on CDT's institutional investor holdings. Which institutional investors have been buying Conduit Pharmaceuticals' stock? The following institutional investors have purchased Conduit Pharmaceuticals' stock in the last 24 months: Rhumbline Advisers ($1.01M), Citadel Advisors LLC ($336.28K), Geode Capital Management LLC ($157.31K), and Barclays PLC ($54.52K). How much institutional buying is happening at Conduit Pharmaceuticals? Institutional investors have bought a total of 1,556,773 shares in the last 24 months. This purchase volume represents approximately $160.19M in transactions. Related Companies GENPREX Major Shareholders Nuvilex Major Shareholders AIM ImmunoTech Major Shareholders Silexion Therapeutics Major Shareholders Alaunos Therapeutics Major Shareholders Omega Therapeutics Major Shareholders IN8bio Major Shareholders Sunshine Biopharma Major Shareholders Cardio Diagnostics Major Shareholders Incannex Healthcare Major Shareholders This page (NASDAQ:CDT) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CDT Stock Alerts